EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudiePragmatische Studie

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

Pragmatische randomisierte Studie zu Afatinib versus Chemotherapie bei Patient:innen mit nicht-kleinzelligem Lungenkarzinom mit seltenen EGFR-Mutationen: ACHILLES/TORG1834

Satoru Miura iD, Hiroshi Tanaka, Toshihiro Misumi iD, Hiroshige Yoshioka iD, Takaaki Tokito, Tatsuro Fukuhara iD, Yuki Sato iD, Yoshimasa Shiraishi iD, Katsuhiko Naoki iD, Hiroaki Akamatsu iD, Ou Yamaguchi iD, Toshihide Yokoyama und 14 weitere

Journal of Clinical Oncology · 20.06.2025 · 43 (18) · 2049-2058

DOI: 10.1200/jco-24-02007 ↗

Auf einen Blick

Afatinib verlängerte in dieser randomisierten Studie das progressionsfreie Überleben gegenüber Chemotherapie. Die Studie wurde nach der Interimsanalyse vorzeitig beendet.

Fragestellung

Ist Afatinib bei nicht vorbehandeltem nicht-squamösem NSCLC mit sensitiven seltenen EGFR-Mutationen der Chemotherapie überlegen?

Methode

Randomisierte, offene Studie in 51 japanischen Zentren; 2:1-Zuteilung zu Afatinib oder Platin/Pemetrexed; primärer Endpunkt PFS; geplante Interimsanalyse.

Ergebnisse

109 Patient:innen. Medianes PFS: 10,6 vs. 5,7 Monate; Hazard Ratio 0,421 (95 %-KI 0,251–0,706); P = .0010. ORR unter Afatinib 61,7 % insgesamt.

Einschränkungen

Die Studie wurde nach der Interimsanalyse vorzeitig beendet.

Schlussfolgerung der Autor:innen

Afatinib sollte als Standard-Initialtherapie für Patient:innen mit NSCLC und sensitiven seltenen EGFR-Mutationen betrachtet werden.

Kernaussagen

  • Afatinib verlängerte das PFS gegenüber Chemotherapie.
  • Medianes PFS: 10,6 vs. 5,7 Monate.
  • Häufige Grad-3-oder-höher-AEs: Diarrhö, Paronychie, Rash.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2025. Verfasst von Satoru Miura und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 23 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor ( EGFR ) mutations. METHODS This randomized, open-label study was performed at 51 Japanese institutions and recruited treatment-naïve patients with nonsquamous NSCLC with uncommon EGFR mutations, excluding exon 20 insertions and T790M mutations. Patients were randomly assigned 2:1 to receive afatinib (30 or 40 mg orally, at the treating physician's discretion) or a combination of platinum (cisplatin or carboplatin) and pemetrexed, followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, and safety. A prespecified interim analysis was planned to provide clinically meaningful information promptly, along with a crossover recommendation if necessary. RESULTS A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was significantly longer in patients receiving afatinib than in those undergoing chemotherapy (10.6 v 5.7 months; hazard ratio, 0.421 [95% CI, 0.251 to 0.706]; P = .0010). ORRs to afatinib were similar across the overall population and among participants with major uncommon (G719X, L861Q, and S768I), compound, and other mutations (61.7%, 55.8%, 72.7%, and 60.0%, respectively). The most common grade 3 or higher adverse events were diarrhea, paronychia, and rash for afatinib, and appetite loss and nausea for chemotherapy. CONCLUSION Afatinib should be considered the standard initial therapy for patients with NSCLC with sensitizing uncommon EGFR mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AfatinibCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedErbB ReceptorsAgedPemetrexedAdultCarboplatinCisplatinAged, 80 and overProgression-Free Survival

Substanzen

AfatinibErbB ReceptorsEGFR protein, humanPemetrexedCarboplatinCisplatin

Autor:innen und Institutionen

  • Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Data Science, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
  • Department of Respiratory Medicine, Miyagi Cancer Center, Natori-shi, Japan.
  • Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe-shi, Japan.

ORCID-Profile: Satoru Miura, Toshihiro Misumi, Hiroshige Yoshioka, Tatsuro Fukuhara, Yuki Sato, Yoshimasa Shiraishi, Katsuhiko Naoki, Hiroaki Akamatsu, Ou Yamaguchi, Shoichi Kuyama, Kazumi Nishino, Naoki Furuya, Takayasu Kurata, Terufumi Kato, Satoshi Ikeda, Hidehito Horinouchi, Yuichi Takiguchi, Kentaro Tanaka, Yasuhiro Goto, Hiroaki Okamoto

Zitieren

APA

Miura, S., Tanaka, H., Misumi, T., Yoshioka, H., Tokito, T., Fukuhara, T., Sato, Y., Shiraishi, Y., Naoki, K., Akamatsu, H., Yamaguchi, O., Yokoyama, T., Kuyama, S., Nishino, K., Furuya, N., Kurata, T., Kato, T., Ikeda, S., Horinouchi, H., …, & Thoracic Oncology Research Group and all ACHILLES investigators (2025). Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. Journal of Clinical Oncology, 43(18), 2049-2058. https://doi.org/10.1200/jco-24-02007

Vancouver

Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, et al. Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. Journal of Clinical Oncology. 2025;43(18):2049-2058. doi:10.1200/jco-24-02007

BibTeX
@article{Miura2025,
  author = {Miura, Satoru and Tanaka, Hiroshi and Misumi, Toshihiro and Yoshioka, Hiroshige and Tokito, Takaaki and Fukuhara, Tatsuro and Sato, Yuki and Shiraishi, Yoshimasa and Naoki, Katsuhiko and Akamatsu, Hiroaki and Yamaguchi, Ou and Yokoyama, Toshihide and Kuyama, Shoichi and Nishino, Kazumi and Furuya, Naoki and Kurata, Takayasu and Kato, Terufumi and Ikeda, Satoshi and Horinouchi, Hidehito and Ichihara, Eiki and Mori, Masahide and Takiguchi, Yuichi and Tanaka, Kentaro and Goto, Yasuhiro and Okamoto, Hiroaki and Thoracic Oncology Research Group and all ACHILLES investigators, Thoracic Oncology Research Group and all ACHILLES investigators},
  title = {Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {18},
  pages = {2049--2058},
  doi = {10.1200/jco-24-02007}
}
Kostenlos starten →